| S7711 |
CH-223191
|
CH-223191 is a potent and specific aryl hydrocarbon receptor (AhR) antagonist with IC50 of 30 nM.
|
-
Cells, 2025, 14(8)605
-
Chem Biol Interact, 2025, 412:111478
-
Front Nutr, 2025, 12:1500293
|
|
| S2858 |
Stemregenin 1 (SR1)
|
StemRegenin 1 (SR1) is an aryl hydrocarbon receptor (AhR) inhibitor with IC50 of 127 nM in a cell-free assay.
|
-
Cell, 2025, S0092-8674(25)01149-3
-
Nat Commun, 2025, 16(1):2384
-
Cell Rep Med, 2025, 6(8):102297
|
|
| S8995 |
BAY 2416964
|
BAY 2416964 (compound 192) is a potent and orally active antagonist of aryl hydrocarbon receptor (AhR) with an IC50 of 341 nM. This compound has the potential in the treatment of solid tumours.
|
-
Ecotoxicol Environ Saf, 2025, 290:117743
-
JBMR Plus, 2025, 9(6):ziaf067
-
NAR Genom Bioinform, 2025, 7(2):lqaf052
|
|
| S6560 |
PDM2
|
PDM2 is a potent and selective aryl hydrocarbon receptor (AhR) antagonist.
|
-
Cancer Cell Int, 2021, 21(1):538
|
|
| S6926 |
GNF351
|
GNF351 is a potent antagonist of the aryl hydrocarbon receptor (AHR). This compound interacts directly with the AHR ligand binding pocket and competes with a well-characterised photoaffinity AHR ligand for binding to the AHR with an IC50 of 62 nM.
|
-
Front Pharmacol, 2021, 12:655281
|
|
| S0155 |
PDM-11
|
PDM-11 is a derivative of resveratrol that exhibits stronger antagonist affinity for arylhydrocarbon receptors (AhR) than resveratrol, without any affinity for the estrogen receptor.
|
|
|
| S1177 |
PD 98059
|
PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR) and functions as an AHR antagonist.
|
-
Nat Commun, 2025, 16(1):212
-
Adv Sci (Weinh), 2025, 12(28):e2502634
-
Theranostics, 2025, 15(6):2624-2648
|
|